AFP — AFT Pharmaceuticals Share Price
Last Trade - 00:00- AU$441.10m
- AU$478.43m
- NZ$113.11m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.7 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | 1.18% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Mar | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NZ$m | 69.2 | 81.18 | 85.13 | 105.6 | 113.11 | 130.76 | 150.63 | 12.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +248.27 | +110.83 | +40.65 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AFT Pharmaceuticals Limited is a pharmaceutical distributor and developer of pharmaceutical intellectual property. The Company's segments include New Zealand, Australia, Asia and Rest of World. The Company's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The Company's NasoSURF Nebuliser is in pilot scale production. The Company is focused on conducting clinical for Maxigesic oral dose forms. The Company is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
Directors
- David Flacks
- Hartley Campbell Atkinson
- Malcolm Dennis Tubby
- Calvin Mackenzie
- Marree Atkinson
- Louise Clayton
- Scott Crawford
- Vladimir Ilievski
- Murray Keith
- Ioana Stanescu
- Brendon Woodhead
- Anita Baldauf
- Jon Lamb
- John Wilson
- Ted Witek
- Last Annual
- March 31st, 2021
- Last Interim
- March 31st, 2021
- Incorporated
- September 4th, 1997
- Public Since
- December 22nd, 2015
- No. of Shareholders
- 2,154
- No. of Employees
- 94
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 104,583,875
- Address
- Level 1, 129 Hurstmere Road, AUCKLAND, 0622
- Web
- http://www.aftpharm.com/
- Phone
- +64 94880232
- Auditors
- Deloitte
Latest News for AFP
Upcoming events for AFP
AFT Pharmaceuticals Ltd Annual Shareholders Meeting
AFT Pharmaceuticals Ltd Annual Shareholders Meeting
Similar to AFP
ALTHEA group ORD
Australian Stock Exchange - SEATS
AUSCANN group ORD
Australian Stock Exchange - SEATS
AVECHO BIOTECHNOLOGY ORD
Australian Stock Exchange - SEATS
BENITEC BIOPHARMA PVT PL ORD
Australian Stock Exchange - SEATS
CANN GLOBAL ORD
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:57 UTC, shares in AFT Pharmaceuticals are trading at AU$4.23. This share price information is delayed by 15 minutes.
Shares in AFT Pharmaceuticals last closed at AU$4.23 and the price had moved by +1.2% over the past 365 days. In terms of relative price strength the AFT Pharmaceuticals share price has underperformed the ASX All Ordinaries Index by -19.83% over the past year.
The overall consensus recommendation for AFT Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
AFT Pharmaceuticals does not currently pay a dividend.
AFT Pharmaceuticals does not currently pay a dividend.
AFT Pharmaceuticals does not currently pay a dividend.
To buy shares in AFT Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$4.23, shares in AFT Pharmaceuticals had a market capitalisation of AU$441.10m.
Here are the trading details for AFT Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AFP
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
AFT Pharmaceuticals does not currently have a style classification.
The analyst consensus target price for shares in AFT Pharmaceuticals is AU$4.64. That is 9.72% above the last closing price of AU$4.23.
Analysts covering AFT Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of NZ$0.16 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AFT Pharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -12.36%.
As of the last closing price of AU$4.23, shares in AFT Pharmaceuticals were trading -4.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AFT Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 42.28. The shares last closed at AU$4.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AFT Pharmaceuticals' management team is headed by:
- David Flacks -
- Hartley Campbell Atkinson -
- Malcolm Dennis Tubby -
- Calvin Mackenzie -
- Marree Atkinson -
- Louise Clayton -
- Scott Crawford -
- Vladimir Ilievski -
- Murray Keith -
- Ioana Stanescu -
- Brendon Woodhead -
- Anita Baldauf -
- Jon Lamb -
- John Wilson -
- Ted Witek -
We do not have data on AFT Pharmaceuticals' shareholders